• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    EVP & Chief Technology Officer Hanly Ann M. sold $133,936 worth of shares (14,168 units at $9.45), decreasing direct ownership by 11% to 117,901 units (SEC Form 4)

    2/25/25 3:43:32 PM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HANLY ANN M.

    (Last) (First) (Middle)
    C/O VIR BIOTECHNOLOGY, INC.
    1800 OWENS STREET, SUITE 900

    (Street)
    SAN FRANCISCO CA 94158

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vir Biotechnology, Inc. [ VIR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP & Chief Technology Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/24/2025 S(1) 14,168 D $9.4534 117,901 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
    Remarks:
    /s/ Vanina de Verneuil, Attorney-In-Fact 02/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    9/9/2022$15.00Underweight
    Morgan Stanley
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Baird
    More analyst ratings

    $VIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vir Biotechnology Inc.

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      10/18/24 12:29:43 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      2/13/24 5:17:30 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vir Biotechnology Inc. (Amendment)

      SC 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)

      2/13/24 5:00:42 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer De Backer Marianne sold $474,239 worth of shares (79,712 units at $5.95), decreasing direct ownership by 9% to 769,505 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      4/4/25 4:23:39 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP and General Counsel De Verneuil Vanina sold $67,402 worth of Common Stock (7,373 units at $9.14), decreasing direct ownership by 8% to 79,460 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      2/27/25 12:39:28 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Scangos George A sold $95,063 worth of shares (10,056 units at $9.45), decreasing direct ownership by 1% to 698,239 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      2/25/25 3:44:56 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    SEC Filings

    See more
    • Vir Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

      5/9/25 8:23:53 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vir Biotechnology, Inc. (0001706431) (Filer)

      5/7/25 4:13:38 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vir Biotechnology Inc.

      DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)

      4/17/25 8:40:10 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Leadership Updates

    Live Leadership Updates

    See more
    • Vir Biotechnology Appoints Jason O'Byrne as Chief Financial Officer

      – Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation

      9/10/24 8:05:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and

      10/30/23 8:00:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

      HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart + elebsiran without or with PEG-IFNα, respectively As previously announced, Phase 3 development in chronic hepatitis B to occur only with a global development and commercialization partner, which has not been secured Vir Biotechnology to streamline the final stages of MARCH Phase 2 study to ensure continued participant benefit and safety, while applying continued financial stewardship The Company reiterates cash runway guidance into mid-2027, based on the current operating plan The Company remains committed to its chronic hepatitis delta program, based on t

      5/9/25 6:00:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

      - Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

      5/7/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

      4/30/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Financials

    Live finance-specific insights

    See more
    • Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

      - Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

      5/7/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

      Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

      4/30/25 4:05:00 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

      Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,

      3/21/25 7:10:00 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vir Biotechnology downgraded by JP Morgan with a new price target

      JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously

      1/29/24 7:27:38 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology downgraded by BofA Securities with a new price target

      BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously

      9/8/23 7:28:27 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vir Biotechnology upgraded by JP Morgan with a new price target

      JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously

      3/6/23 7:36:08 AM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care